CY2027 Medicare Physician Fee Schedule: What Specialty Practices Must Do Before January 1

The comment period on the CY2027 Medicare Physician Fee Schedule Proposed Rule closed on September 14, 2026. CMS is now in its finalization window. If the rule takes effect as proposed on January 1, 2027, the Modifier 25 change alone will strip hundreds of thousands of dollars in annual revenue from specialty practices that don't adapt their billing workflows in the next 91 days.

This is not speculation. The proposed rule is published (Federal Register 91 FR 43842, July 16, 2026). The numbers are specific. And the practices with the highest exposure — dermatology, ENT, orthopedics, and every procedural specialty that routinely bills same-day E/M plus procedure — have a narrow window to model the damage and prepare before January 1.

What CMS Is Proposing for Modifier 25

Today, Modifier 25 allows a provider to bill an E/M visit on the same day as a procedure when the E/M is for a separately identifiable condition. A dermatologist performs a biopsy and also evaluates an unrelated rash in the same visit. An ENT removes nasal polyps and separately addresses new hearing loss. An orthopedic surgeon does a cortisone injection and also manages a chronic back pain complaint. In each case, the E/M visit and the procedure receive full, separate payment.

The CY2027 proposed rule changes the math: the lower-paying service gets cut by 50%. If the E/M visit pays less than the procedure, the E/M payment is halved. If the E/M visit pays more, the procedure payment is halved. Either way, the combined reimbursement for a same-day E/M + procedure encounter drops significantly.

For a dermatology practice billing a Level 4 E/M (99214, approximately $130 Medicare) same-day with a skin biopsy (11102, approximately $110 Medicare), the E/M currently pays in full. Under the proposal, the biopsy payment would be cut to approximately $55. Multiply that across every biopsy + E/M encounter in a year — for a high-volume derm practice, that is hundreds of encounters per month.

Which Specialties Get Hit Hardest

The Modifier 25 change is not evenly distributed. It targets practices where same-day E/M + procedure billing is a core revenue pattern:

Dermatology

Same-day E/M + procedure billing represents 20–35% of total dermatology billing volume. Every Mohs surgery visit that includes a separate E/M evaluation. Every biopsy appointment where the patient also discusses a new skin concern. Every cosmetic consultation combined with a medical dermatology E/M. The 50% payment reduction on the lower-paying service compounds across hundreds of encounters monthly. Practices that haven't modeled the dollar impact are flying blind into January.

ENT

ENT practices routinely perform in-office procedures — endoscopy, cerumen removal, audiometric testing — on the same day as E/M visits for new or separate complaints. Multi-facility surgical groups face compounding exposure: the Modifier 25 cut stacks on top of global period billing complexity, cross-referral coordination overhead, and prior authorization requirements that already delay surgical revenue.

Orthopedics

The American Association of Orthopaedic Surgeons warned the CY2027 proposed changes would cause "irreparable damage by instituting acute cuts to orthopedic care that will change the face of American healthcare indefinitely." Joint injections, fracture care, and minor surgical procedures routinely pair with same-day E/M visits. Orthopedic practices with high Medicare patient volumes face the steepest per-encounter revenue loss.

All Procedural Specialties

Gastroenterology, ophthalmology, podiatry, pain management, urology — any specialty where in-office procedures are commonly performed alongside separately identifiable E/M evaluations takes a revenue hit under this rule. The more procedural the practice, the deeper the cut.

The Compounding Cuts: Modifier 25 Is Not the Only Blow

The Modifier 25 change is the headline, but the CY2027 PFS delivers multiple simultaneous payment pressures:

Conversion Factor Reduction

Without Congressional action, the PFS conversion factor drops -1.19% for advanced APM participants and -1.68% for non-participants in 2027. Every procedure and E/M code pays slightly less across the board, before the Modifier 25 cut is applied.

G2211 Shift — Minimal Help for Specialists

The G2211 longitudinal care add-on code moves from a flat payment to 16% of the E/M service value (32% for qualifying ACO participants). This primarily benefits primary care and behavioral health providers who manage chronic conditions over time. Procedural specialists without ACO alignment see minimal revenue from G2211, making the Modifier 25 cut a net negative without a meaningful offset.

Budget Neutrality Redistribution

CMS operates the PFS under budget neutrality: gains for one specialty are funded by cuts to others. The CY2027 proposed rule shifts payment toward primary care and behavioral health. The Indirect Practice Cost Index (IPCI) is being eliminated over two years, hitting radiology, anesthesiology, and other high-overhead specialties with additional indirect cost reductions on top of the direct Modifier 25 cut.

OBBBA Medicaid State-Directed Payment Phase-Down

The One Big Beautiful Bill Act (OBBBA) phases down Medicaid state-directed payments (SDPs) starting 2028. New limits cap supplemental Medicaid payments at 110% of Medicare rates in non-expansion states and 100% in expansion states — down from current levels that can supplement up to average commercial rates.

The top 8 states by excess SDP exposure (KFF analysis):

The phase-down uses 10-percentage-point annual increments, giving practices 18 months to model the combined impact of PFS Modifier 25 cuts, conversion factor reductions, and Medicaid SDP phase-downs. For a Texas specialty practice with a mixed Medicare/Medicaid panel, these three changes compound into a significant revenue contraction that demands workflow changes now — not after the final rule drops.

What AI Billing Automation Does Differently

The CY2027 PFS changes create two categories of work for specialty practices: exposure modeling (understanding how much revenue is at risk) and workflow preparation (adapting billing and documentation practices before January 1). Both are where AI billing automation delivers immediate value.

Real-Time Modifier 25 Eligibility Checking

AI validates Modifier 25 eligibility at the point of claim assembly — before submission. Does the encounter documentation establish a separately identifiable E/M condition? Does the HPI, ROS, exam, and MDM support a distinct clinical evaluation beyond the procedure indication? Under the current rule, weak documentation risks a denial. Under the CY2027 rule, weak documentation risks both a denial and a 50% payment cut on every encounter where Modifier 25 is applied without adequate support.

E/M Documentation Completeness Verification

For every same-day E/M + procedure encounter, AI verifies four documentation elements before the claim leaves the practice:

• Separate HPI — The history of present illness for the E/M condition must be distinct from the procedure indication
• Separate ROS — Review of systems relevant to the E/M complaint, not duplicated from the procedural workup
• Separate exam findings — Physical examination documented for the E/M condition independent of the procedure site
• Separate MDM — Medical decision-making that addresses the E/M condition as a distinct clinical problem

When any element is missing or ambiguous, AI routes the encounter back for documentation correction before claim submission. Under the proposed 50% cut, every properly documented Modifier 25 encounter represents preserved revenue that would otherwise be lost to insufficient documentation.

Payer-Mix Revenue Exposure Modeling

Not all payers follow Medicare fee schedule changes. Commercial payers set their own Modifier 25 policies. AI billing systems model the revenue impact of the CY2027 PFS change across your specific payer mix — isolating Medicare fee-for-service exposure from Medicare Advantage (which may or may not adopt the rule immediately) from commercial payers (which follow independent policies). This granular modeling prevents the common mistake of assuming the Modifier 25 change applies uniformly across all revenue.

Fee Schedule Optimization

With conversion factor cuts and Modifier 25 reductions compounding, AI identifies opportunities to optimize fee schedules across payers. Which commercial contracts should be renegotiated before January? Which payer-specific billing patterns offset Medicare losses? Where does coding accuracy (capturing the correct E/M level based on documentation complexity) recover revenue that sloppy coding leaves behind? AI surfaces these opportunities proactively rather than waiting for the year-end revenue report to reveal the damage.

Proactive OBBBA Payer-Mix Analysis

For practices in the 37+ states facing Medicaid SDP phase-downs, AI maps the overlap between CY2027 PFS cuts and OBBBA exposure. A Texas practice that loses Modifier 25 revenue on Medicare patients and faces $3.5 billion in state-wide Medicaid supplemental payment reductions needs a payer-mix strategy that accounts for both pressures simultaneously — not one at a time.

The 91-Day Preparation Window

Between today and January 1, 2027, specialty practices have a finite window to prepare:

1. Model the exposure. Pull every Modifier 25 claim from the last 12 months. Calculate the revenue at risk under a 50% payment reduction on the lower-paying service. Segment by payer — Medicare FFS, Medicare Advantage, commercial — because the impact is not uniform.
2. Audit documentation quality. How many of your Modifier 25 encounters actually meet the separately identifiable standard with four-element documentation (HPI, ROS, exam, MDM)? If the answer is less than 90%, you have a documentation training gap that will cost revenue under the new rule.
3. Pre-stage billing workflow changes. Configure your billing system to apply the new payment logic on January 1. Identify encounters where unbundling the E/M visit to a separate date of service may be clinically appropriate and financially advantageous.
4. Negotiate commercial contracts. Commercial payers are not required to follow the Medicare Modifier 25 change. Proactively confirm with each commercial payer whether they will adopt the new rule — and renegotiate terms where possible.
5. Model OBBBA exposure. For practices in affected states, project the combined revenue impact of PFS cuts and Medicaid SDP phase-downs. Identify whether payer-mix shifts, service-line adjustments, or volume strategies can offset the compounding pressure.

AI billing automation handles steps 1, 2, and 3 at scale — modeling exposure across thousands of historical claims, auditing documentation completeness on every future encounter, and auto-updating billing logic when the final rule is published. The manual alternative is a billing manager with a spreadsheet, a 91-day runway, and a team already running at 9% denial rates and 42 AR days (AMS Solutions 2026).

The CY2027 PFS final rule has not been published. The comment period is closed. The finalization window is open. Practices that wait for the final rule to start preparing will spend January scrambling. Practices that model their exposure now will be ready on day one.